Heumann Pharma Gmbh & Co.

Kurt-Henning Ahrens

Peter Morsdorf

Helmut Schickaneder

Heidrun Engler

Rolf Herter

Walter Schunack

Volker Pfahlert

Armin Buschauer

Reinhold Weidner

Gert Baumann

A new imidazolyl propyl guanidine derivative corresponding to formula I ##STR1## is described, which is distinguished by a combination of particularly advantageous properties for the treatment of diseases of the heart and circulation.

Imidazolyl propyl guanidine derivative and a pharmaceutical composition

New diazine derivatives corresponding to the general formula I ##STR1## and the physiologically acceptable salts thereof are described. The compounds according to the invention are new positive inotropic compounds having a higher and/or more selective action than compounds hitherto known and are therefore suitable for the treatment and prevention of diseases of the heart and circulation.

Cardiotonic thiadiazine derivatives

New 6-phenyldihydro-3(2H)-pyridazinones corresponding to the following general formula ##STR1## are described. These compounds are readily prepared in a form suitable for oral administration and are distinguished by a high positive inotropic action and have only a slight effect on blood pressure and cardiac frequency. A process for their preparation and pharmaceutical preparations containing these compounds are also described.

Piperazine substituted 6-phenyldihydro-3(2H)-pyridazinones, and

New imidazolyl guanidine derivatives corresponding to the following general formula ##STR1## are described. These compounds may be used in cardiac diseases, certain forms of hypertension and in diseases of arterial occlusion on account of their agonistic action on histamine-H.sub.2 receptors and in part their additional H.sub.1 -antagonistic receptor activity.

Growing community of inventors

Nuremberg, Germany

Kurt-Henning Ahrens